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Stimulator of type I IFN genes (TMEM173; STI NG) is a 
cytosolic nucleic acid sensor that plays a critical role in the 
cell-intrinsic innate immune response to microbial DNA and 
cyclic dinucleotides, as well as to aberrant host DNA (Stet-
son, 2012; Gao et al., 2013; Li et al., 2016). Genetic deletion 
of STI NG in mice results in impaired immunity to a variety 
of pathogens including bacteria and viruses (Ishikawa et al., 
2009; Schoggins et al., 2014; Parker et al., 2015). In humans, 
several autosomal dominant de novo or inherited mutations 
in STI NG have been reported in STI NG-associated vasculop-
athy with onset in infancy (SAVI) and patients with familial 
chilblain lupus (Jeremiah et al., 2014; Liu et al., 2014; Picard 
et al., 2016; König et al., 2017). One of the most frequently 
found SAVI mutations is STI NG N154S (N153S in mouse or-
thologue), a mutation that is thought to constitutively activate 
IRF3 to induce transcription of IFN-β and IFN-stimulated 
genes (ISGs; Liu et al., 2014). SAVI patients with the STI NG 
N154S mutation develop systemic inflammatory disease char-
acterized by vasculopathic lesions that affect the lung and skin 
(Liu et al., 2014). The resulting clinical syndrome includes in-
terstitial lung disease, ulcerative skin lesions, digital ischemia, 
and T cell cytopenia (Liu et al., 2014; Picard et al., 2016).
STI NG resides on the ER and is activated by cGAMP, 
a cyclic dinucleotide second messenger that is produced by 
cGAMP synthase (cGAS) upon detection of cytosolic host or 
microbial DNA (Stetson, 2012; Schoggins et al., 2014; West 
et al., 2015; Li et al., 2016). Binding of cGAMP to STI NG 
triggers a conformational change in the STI NG C terminus 
(Ouyang et al., 2012) and subsequent ER-to-vesicle traffick-
ing (Dobbs et al., 2015), which activates downstream effectors 
including TANK-binding kinase 1 (TBK1; Tanaka and Chen, 
2012) and IκB kinase (Ishikawa and Barber, 2008). TBK1 
phosphorylates IRF3, which leads to IRF3 translocation into 
the nucleus and transcriptional activation of IFN-β and ISGs 
(Li et al., 2016; Wang et al., 2016). Activation of the type I 
IFN response via IRF3 is thought to be the driving force 
behind SAVI disease pathogenesis (Liu et al., 2014), although 
this hypothesis was not previously tested experimentally in 
an animal model of the disease. Interestingly, one recent study 
provided evidence that abnormalities in T cell proliferation 
in human patients with SAVI occur independently of any 
interaction with TBK1 and IRF3 (Cerboni et al., 2017). 
Thus, there is a need for models of SAVI that will allow in 
vivo testing of previously hypothesized mechanisms of dis-
ease pathogenesis, beyond cell culture studies of IRF3 acti-
vation. Here, we describe the generation of STI NG N153S 
knock-in mice as a model of SAVI. Like SAVI patients, the 
Patients with stimulator of interferon genes (STI NG)–associated vasculopathy with onset in infancy (SAVI) develop systemic 
inflammation characterized by vasculopathy, interstitial lung disease, ulcerative skin lesions, and premature death. Autosomal 
dominant mutations in STI NG are thought to trigger activation of IRF3 and subsequent up-regulation of interferon (IFN)- 
stimulated genes (ISGs) in patients with SAVI. We generated heterozygous STI NG N153S knock-in mice as a model of SAVI. 
These mice spontaneously developed inflammation within the lung, hypercytokinemia, T cell cytopenia, skin ulcerations, and 
premature death. Cytometry by time-of-flight (CyTOF) analysis revealed that the STI NG N153S mutation caused myeloid cell 
expansion, T cell cytopenia, and dysregulation of immune cell signaling. Unexpectedly, we observed only mild up-regulation of 
ISGs in STI NG N153S fibroblasts and splenocytes and STI NG N154S SAVI patient fibroblasts. STI NG N153S mice lacking IRF3 
also developed lung disease, myeloid cell expansion, and T cell cytopenia. Thus, the SAVI-associated STI NG N153S mutation 
triggers IRF3-independent immune cell dysregulation and lung disease in mice.
STI NG-associated vasculopathy develops independently  
of IRF3 in mice
James D. Warner,1* Ricardo A. Irizarry-Caro,4* Brock G. Bennion,3 Teresa L. Ai,3 Amber M. Smith,1 
Cathrine A. Miner,1 Tomomi Sakai,4 Vijay K. Gonugunta,4 Jianjun Wu,4 Derek J. Platt,2 Nan Yan,4,5  
and Jonathan J. Miner1,2,3
1Department of Medicine, 2Department of Molecular Microbiology, and 3Department of Pathology and Immunology, Washington University School of Medicine,  
St. Louis, MO
4Department of Immunology and 5Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX
© 2017 Warner et al. This article is distributed under the terms of an Attribution–Noncommercial–Share 
Alike–No Mirror Sites license for the first six months after the publication date (see http ://www .rupress .org 
/terms /). After six months it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 4.0 International license, as described at https ://creativecommons .org /licenses /by -nc -sa /4 .0 /).
*J.D. Warner and R.A. Irizarry-Caro contributed equally to this paper.
Correspondence to Jonathan J. Miner: jonathan.miner@wustl.edu; Nan Yan: nan.
yan@utsouthwestern.edu
Abbreviations used: cGAS, cGAMP synthase; CyTOF, cytometry by time-of-flight; ISG, 
IFN-stimulated gene; qRT-PCR, quantitative RT-PCR; SAVI, STI NG-associated vascu-































































Mouse model of STI NG-associated vasculopathy | Warner et al.2
mice developed T cell cytopenia, myeloid cell expansion, and 
spontaneous pulmonary inflammation, which occurred inde-
pendently of IRF3 in mice.
RESULTS
STI NG N153S mice develop spontaneous lung and skin 
disease, causing premature death
The original description of SAVI found that four of six pa-
tients had the STI NG N154S mutation (Liu et al., 2014; 
N153S in mouse STI NG), a mutation that we previously 
confirmed to cause up-regulation of type I IFN in 293T 
cell assays (Dobbs et al., 2015). Thus, we chose to introduce 
the STI NG N153S mutation in mice to produce a model 
of SAVI. Using CRI SPR/Cas9, we generated heterozygous 
STI NG N153S mice by introducing a DNA oligonucle-
otide donor containing a two-nucleotide missense mutation 
into exon 5 of TMEM173 (STI NG), which resulted in re-
placement of asparagine 153 with serine (STI NG N153S; 
Fig.  1  A). Homozygous knock-in mice did not survive 
gestation, whereas adult STI NG N153S heterozygous ani-
mals (STI NG N153S mice) developed spontaneous disease 
characterized by splenomegaly (Fig. 1 B), pleural effusions 
(Fig. 1 C), and ulcerative skin lesions of the extremities of 
five mice and on the head of one 9-mo-old STI NG N153S 
animal (Fig. 1 D). Severe respiratory distress occurred fre-
quently, required euthanasia, and was sometimes observed 
during late pregnancy in STI NG N153S dams that were 
unable to survive labor (Fig. 1 E). Histopathological eval-
uation of the lung revealed chronic perivascular inflamma-
tion with heterogeneous immune cell infiltration (Fig. 2 A, 
black arrows) and organized thrombosis in pulmonary 
blood vessels (Fig. 2 A, red arrows). Higher-magnification 
images (Fig. 2 B) and flow cytometric analysis of immune 
cells in the lungs of STI NG N153S mice revealed substan-
tially increased numbers of immune cells (two- to fourfold, 
P < 0.05), predominantly consisting of CD19+ B cells and 
CD11b+ myeloid cells, with smaller numbers of CD4+ and 
CD8+ T cells (Fig. S1). Because SAVI patients frequently 
develop interstitial lung disease, we performed a histologi-
cal assessment for pulmonary fibrosis by Gomori trichrome 
staining of STI NG N153S lungs, but we found no evidence 
of pulmonary fibrosis, even in animals that were evaluated at 
necropsy after spontaneous death caused by respiratory dis-
tress (Fig. 2 C). Histopathological assessment of skin lesions 
revealed mixed immune cell infiltration, ulceration, and 
scarring (Fig. 2 D). Some features of disease are shared in 
SAVI and systemic lupus erythematosus (Balada et al., 2016), 
but unlike many patients with systemic lupus, SAVI patients 
do not develop glomerulonephritis. Consistent with SAVI 
in humans, we found no evidence of inflamed or abnor-
mal glomeruli in STI NG N153S mice (Fig. 2 E). However, 
histopathological examination of the spleen consistently 
demonstrated abnormal architecture (Fig.  2 F), suggesting 
that the STI NG N153S mutation may trigger immune cell 
dysregulation in secondary lymphoid organs.
Because some SAVI patients develop autoantibodies 
(Liu et al., 2014), we quantitated levels of total IgM and IgG 
antibodies and performed autoantigen array analysis of serum 
from STI NG N153S mice and WT littermate control an-
imals. Three of five STI NG N153S mice produced higher 
levels of IgM but not IgG autoantibodies compared with WT 
littermates (Fig. 3). However, all five of the STI NG N153S 
Figure 1. Spontaneous disease and mor-
tality in STI NG N153S mice. (A) Electro-
pherogram of WT and STI NG N153S mutant 
alleles within exon 5. (B) Spleens from WT 
littermate control and STI NG N153S mice. 
(C) STI NG N153S mouse lungs with surround-
ing pleural effusions, indicated by the yellow 
arrows. (D) Representative skin ulcerations 
(yellow arrows) on the extremities and head of 
STI NG N153S mice. (E) Mortality was assessed 
in STI NG N153S male and female mice (n = 21) 
for 180 d. Three pregnant female mice (#) suc-
cumbed to disease. No mortality occurred in 












mice had severe lung disease, including animals without de-
tectable autoantibodies, suggesting that autoantibodies are 
not required for disease pathogenesis in mice. A multiplexed 
cytokine assay performed on the serum of 4–6-mo-old 
STI NG N153S mice and WT littermate controls revealed el-
evated levels of multiple cytokines and chemokines including 
TNF, IL-17A, IL-13, G-CSF, MIP-1α, MIP-1β, MCP-1, and 
IL-10 (2–23-fold increase, P < 0.05; Fig. 4). Thus, STI NG 
N153S mice develop hypercytokinemia and spontaneous in-
flammation of the lung and skin.
Figure 2. STI NG N153S mice develop spontaneous perivascular inflammation of the lung. (A) Hematoxylin and eosin (H&E) images of par-
affin-embedded lung sections from 4–5-mo-old STI NG N153S and WT littermate control mice. Pulmonary blood vessels (v) and bronchioles (b) are 
indicated. Top, black arrows indicate perivascular immune cell infiltrate. Bar, 100 µm. Bottom, red arrows indicate organized thrombosis. Bar, 50 µm. 
(B) High-magnification H&E images of WT (left) and STI NG N153S (right) lung sections. Bar, 5 µm. (C) Gomori trichrome staining of WT and STI NG N153S 
lung sections. Bar, 100 µm. (D) H&E staining of WT as well as STI NG N153S skin from the ulcerated skin lesion on a hind limb. Bar, 50 µm. (E) H&E staining 
of representative STI NG N153S and WT littermate glomeruli. Bar, 10 µm. (F) H&E staining of WT and STI NG N153S spleens. Bar, 100 µm. Spleen and kidney 
histology is representative of n = 3 mice per genotype from three independent experiments. Skin histology is representative of n = 2 mice per genotype. 
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The STI NG N153S mutation causes myeloid cell expansion 
and cell-intrinsic T cell cytopenia
SAVI patients were previously reported to have T cell cytope-
nia and impaired myeloid cell differentiation (Liu et al., 2014). 
To begin to characterize immune cells in STI NG N153S 
mice, we used cytometry by time-of-flight (CyTOF) to as-
sess immune cell populations in the spleen (Fig. 5). Although 
we detected no difference in numbers of splenic CD45+ and 
CD19+ cells in STI NG N153S mice, there was a deficiency 
in T cells (22 × 106 CD3+ cells in WT vs. 2.9 × 106 in STI NG 
N153S; P < 0.005), which was more severe, and consistently 
observed, for CD8+ T cells than for CD4+ T cells (Fig.  5, 
A–C and F–H). Additionally, we observed marked expansion 
of Ly6G+ myeloid cells (0.6 × 106 in WT vs. 9.5 × 106 in 
STI NG N153S; P < 0.005; Fig. 5, A–C and I) and imma-
ture myeloid cells (CD11b+cKit+MHC II−; Fig.  5  A). Also, 
in T and NK cells, activation markers including CD44 were 
up-regulated (Fig. 5, J and K), which may occur as a direct 
result of cell-intrinsic STI NG signaling or may reflect an in-
direct consequence of chronic hypercytokinemia.
To test whether T cell cytopenia may result from 
cell-intrinsic effects of the STI NG N153S mutation, we 
generated mixed bone marrow chimeras by comparing WT 
Thy1.1+ versus either WT littermate control or STI NG 
N153S marrow transplanted into CD45.1 recipients (Fig. 6 A). 
In the competition between the Thy1.1+ and STI NG N153S 
donors, CD4+ and CD8+ T cells were predominantly gen-
erated from WT Thy1.1+ bone marrow, revealing that the 
STI NG N153S T cell deficiency is intrinsic to the hemato-
poietic compartment (Fig. 6, B and C). To further evaluate 
the cause of splenic T cell deficiency, we performed CyTOF 
analysis of thymocytes (Fig. 7) and found a decrease in total 
numbers of thymocytes (2.7-fold in STI NG N153S com-
pared with WT, P < 0.005), a large increase in the number and 
percent of thymic B cells (0.13% in WT vs. 2.5% in STI NG 
N153S, P < 0.005), and a lower fraction of double-negative 
T cells (1.8% in WT vs. 1.2% in STI NG N153S, P < 0.005; 
Fig. 7). Although diminished in total number, the percentages 
of individual thymocyte subsets did not suggest a block at 
any specific stage in T cell development. Evaluation of mixed 
bone marrow chimeric mice confirmed diminished STI NG 
N153S T cell numbers at all stages of development, includ-
ing at the DN1 stage, consistent with what was observed in 
mixed chimeric mice (Fig. 7 N). These results suggest that the 
STI NG N153S mutation exerts hematopoietic cell-intrinsic 
deleterious effects on the early stages of thymocyte develop-
ment. This result also is consistent with prior in vitro stud-
ies demonstrating that a different SAVI-associated mutation 
(STI NG V155M) caused cell-intrinsic effects in human T 
cells (Cerboni et al., 2017), although our in vivo findings sug-
Figure 3. Increased IgM autoantibodies in the serum of STI NG 
N153S mice. Immunoglobulin analysis of WT and STI NG N153S mouse 
serum (n = 9). (A and B) Quantitation of total IgG (A) and total IgM (B). 
(C) Heat maps of IgG and IgM autoantibodies against autoantigens. n = 
9 per genotype. ****, P < 0.0001; ns, not significant. Data are the result of 
two independent experiments with four to five samples per experiment 












gest that T cell cytopenia results mostly from cell-intrinsic 
effects on early T cell precursors.
Activation of STAT and mTORC1 signaling in 
STI NG N153S splenocytes
To further investigate the effects of STI NG N153S on cell 
signaling, we used CyTOF to assess phosphorylation status of 
TBK1, STAT1, STAT3, STAT5, SHP2, 4E-BP1, S6, and the 
presence of Ki67, a marker of cellular proliferation. In STI NG 
N153S splenocytes, we observed a pronounced activation of 
the mTORC1 pathway (phospho-S6 and phospho-4E-BP1) 
in immune cell subsets known to express STI NG (mono-
cytes, T cells, NK cells, and cKit+ immature myeloid cells; Liu 
et al., 2014; Kobayashi et al., 2015) as well as increased acti-
vation of STAT3 and STAT5 in monocytes and NK cells, 
respectively (Fig.  8, A and B). These data suggest that the 
STI NG N153S mutation results in activation of mTORC1, 
STAT3, and STAT5 signaling in specific immune cell subsets 
that may occur as a result of either cell-intrinsic or -extrinsic 
effects of the mutation.
Because SAVI patient PBMCs exhibit a type I IFN gene 
expression signature (Liu et al., 2014), we examined whether 
STI NG N153S mice also up-regulate expression of ISGs. 
Using RNA-sequencing, and confirmed by quantitative 
RT-PCR (qRT-PCR), we detected only an approximately 
twofold up-regulation of ISGs in MEFs and splenocytes com-
pared with WT littermate controls (Fig.  9, A and B), sug-
gesting only mild up-regulation of type I IFN signaling. This 
ISG signature is much weaker in comparison to Trex1−/− 
mice, which exhibit constitutive STI NG activation and an 
interferonopathy with clinically distinct manifestations of 
disease (Morita et al., 2004), and in which the majority of 
Figure 4. Hypercytokinemia in STI NG N153S mice. (A–P) Serum was collected from 4–6-mo-old STI NG N153S and WT littermate control mice, and 
cytokine and chemokine levels were measured by Bio-Plex assay (n = 9 mice per group). Data represent the mean from two independent experiments. 
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ISGs within the same panel were markedly elevated (17-fold 
compared with WT littermate controls; Fig. 9, A and B). Be-
cause Trex1−/− cells accumulate self-DNA that constitutively 
activates STI NG through the cGAS-STI NG-TBK1-IRF3 
pathway (Hasan et al., 2013), our results collectively suggest 
that STI NG N153S does not cause potent activation of type 
I IFN signaling in vivo in mice. Next, we decided to correlate 
our findings with human SAVI patient samples and found 
that only one of two SAVI patient fibroblasts with the STI NG 
N154S mutation exhibited significant up-regulation of ISG 
expression (Fig.  9, C and D). Similarly, we did not detect 
enhanced cGAMP-mediated activation of STI NG in patient 
cells compared with healthy controls or in STI NG N153S 
MEFs compared with WT littermate control MEFs (Fig. S2, 
A–F), although we observed up-regulation of ISGs in 293T 
cells that overexpress mouse STI NG N153S in this study (Fig. 
S2 G) and also in our prior study comparing human STI NG 
N154S and mouse STI NG N153S in parallel (Dobbs et al., 
2015). These findings suggest that the STI NG mutations may 
exhibit differential effects in cell lines and in primary cells, 
or that overexpression produces a more pronounced effect 
on expression of ISGs.
SAVI has been postulated to result from STI NG- 
mediated activation of IRF3, which potently up-regulates 
expression of ISGs, so we initially hypothesized that genetic 
deletion of IRF3 would rescue the mice from disease. To test 
this hypothesis, we generated Irf3−/− STI NG N153S mice. 
Unexpectedly, we observed a similar degree of perivascular 
immune cell infiltration in Irf3−/− STI NG N153S mice com-
pared with STI NG N153S control animals (Fig. 9, E and F). 
Conversely, Irf3−/− STI NG N153S MEFs exhibited reduced 
IFIT1 and ISG15 expression compared with STI NG N153S 
MEFs (Fig. 9 G), confirming that IRF3 is required for STI NG 
N153S-dependent up-regulation of IFIT1 and ISG15. IRF7 
is up-regulated in a positive feedback loop downstream of 
IRF3 and IFN-β (Marié et al., 1998; Sato et al., 1998), but we 
did not detect any up-regulation of IRF7 in vivo or in vitro 
(Fig. 9, A–D).
To determine whether IRF3 is required for STI NG 
N153S-mediated myeloid cell expansion and T cell cytopenia, 
Figure 5. WT and STI NG N153S immune cell populations. WT and STI NG N153S splenocytes were analyzed by CyTOF. (A) viSNE map of WT and 
STI NG N153S splenocytes illustrating color-coded cell populations that clustered based on cell surface marker expression. (B) viSNE map indicating the level 
of CD3 marker expression in immune cell populations defined in A. (C) Density plots of immune cell populations defined in A. (D–I) Total number of CD45+ 
(D), CD19+ (E), CD3+ (F), CD4+ (G), CD8+ (H), and Ly6G+ (I) cells in WT littermate control and STI NG N153S splenocytes. Horizontal bars represent the mean 
of n = 6 samples from two independent experiments. **, P < 0.005 by Mann-Whitney test. (J and K) Heat maps illustrating the calculated arcsinh ratios of 
median intensities of CD25, CD11b, and CD44 expression in CD4+ (J, left), CD8+ (J, right), NK1.1+ (K, left), and CD3+CD4−CD8− (CD3+DN; K, right) splenocytes. 












we assessed WT, STI NG N153S, Irf3−/−, and Irf3−/− STI NG 
N153S splenocytes by flow cytometry. We observed simi-
larly increased numbers of Ly6G+ and Ly6C+ myeloid cell 
populations in Irf3−/− STI NG N153S mice and STI NG 
N153S control animals (Fig. 9, H–J; P > 0.7). Additionally, 
the percent and absolute number of CD8+ T cells were simi-
larly reduced in splenocytes from Irf3−/− STI NG N153S and 
STI NG N153S mice (Fig. 9, K and L) compared with their 
respective controls. Thus, lung disease, myeloid cell expansion, 
and CD8+ T cell cytopenia occur independently of IRF3 sig-
naling in this STI NG N153S mouse model of SAVI.
DISCUSSION
Our study demonstrates that a SAVI-associated STI NG mu-
tation causes spontaneous inflammatory lung and skin disease 
in mice. However, certain features of the disease in mice were 
distinct from clinical features of SAVI in humans. For example, 
STI NG N153S mice did not develop pulmonary fibrosis, and 
we did not observe a significant type I IFN gene expression 
signature in mice, which has been reported in humans with 
SAVI. However, species-specific effects of a disease-causing 
mutation are not entirely unexpected. For example, humans 
lacking functional TREX1, which leads to type I IFN pro-
duction caused by constitutive STI NG signaling, develop 
spontaneous brain inflammation (Crow et al., 2006), whereas 
mice lacking Trex1 develop an interferonopathy with myo-
carditis (Morita et al., 2004). In contrast to the differential ef-
fects of Trex1 mutations in humans and mice, STI NG N153S 
mice and SAVI patients have some interesting cross-species 
similarities, including organ-specific inflammation (e.g., skin 
and lung disease) as well as T cell cytopenia.
Up-regulation of ISGs occurs in PBMCs of SAVI pa-
tients (Liu et al., 2014; Picard et al., 2016), but whether type 
I IFN plays a causal role in the human disease remains to be 
determined. Importantly, some of the clinical manifestations 
of SAVI are distinct from other interferonopathies such as 
Aicardi-Goutières syndrome, a disease in which the STI NG 
pathway is chronically activated because of loss of TREX1 
function (Crow and Manel, 2015). One view is that SAVI 
pathogenesis is mediated by IRF3-induced activation of the 
type I IFN response (Liu et al., 2014; Kim et al., 2016; Melki 
et al., 2017), as occurs in other interferonopathies (Crow 
and Manel, 2015; Kim et al., 2016), but this had not previ-
ously been tested experimentally in an animal model with a 
human disease-causing STI NG mutation. We observed only 
mild effects on ISG expression in STI NG N153S MEFs, 
and these effects were abolished in the absence of IRF3 
(Fig. 9 G), demonstrating that there was indeed some mild 
IRF3-dependent up-regulation of certain ISGs in MEFs. Ad-
ditionally, we observed mild up-regulation of ISGs in patient 
fibroblast cell lines bearing the STI NG N154S mutation. 
Our results demonstrate that the STI NG N153S mutation 
causes inflammatory lung and skin disease in mice without 
substantive up-regulation of ISGs in primary cells, without 
up-regulation of IRF7 in vivo or in vitro, and without IRF3, 
a major downstream effector thought to promote disease in 
patients with SAVI. Nevertheless, additional studies in STI NG 
N153S mice lacking the type I IFN receptor are still required 
to completely exclude any contribution of type I IFN in this 
mouse model of SAVI. Given that IRF3 does not play a role 
in the disease in mice, it seems plausible that STI NG muta-
tions in humans also cause disease via other mechanisms and 
that up-regulation of type I IFN in patient PBMCs might 
be an epiphenomenon. Alternatively, mechanisms of disease 
pathogenesis may be entirely distinct in humans with SAVI 
and the STI NG N153S mice, with type I IFN playing a more 
important role in the human disease.
In patients with systemic sclerosis and interstitial lung 
disease, there is an association between type I IFN and pul-
monary fibrosis, suggesting a possible role for type I IFN in 
Figure 6. WT and STI NG N153S mixed bone marrow chimeras. 
(A) Diagram depicting the approach for generation of WT littermate and 
STI NG N153S mixed bone marrow chimeras (n = 10). (B) Representative 
contour plots of circulating CD4+ (top) and CD8+ (bottom) donor T cells. 
(C) Percentage of Thy1.1− WT littermate or STI NG N153S circulating CD4+ 
and CD8+ cells from mixed bone marrow chimeras. Data represent the 
mean of samples collected from n = 10 mice from two independent exper-
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fibrosing lung disease (Eloranta et al., 2010). Based on associ-
ation, pulmonary fibrosis in SAVI patients also may be influ-
enced by type I IFN (Picard et al., 2016). We found that the 
STI NG N153S knock-in mice universally developed chronic 
lung inflammation by age 3–4 mo, but without evidence of 
fibrosis even in mice that were examined after death from 
respiratory distress. However, mice older than 6 mo were not 
assessed. Chronic inflammation may eventually cause fibrosis 
in older animals that survive longer. Alternatively, the relative 
absence of a type I IFN gene expression signature in STI NG 
N153S mice may be one reason the animals failed to develop 
fibrosing lung disease.
STI NG exerts multiple effects on the pathogenesis of 
autoimmune disease. Aside from its capacity to up-regulate 
ISGs, the TREX1-cGAS-STI NG pathway modulates cellular 
senescence (Yang et al., 2017), adaptive immunity (Fu et al., 
2015; Cerboni et al., 2017), and production of proinflamma-
tory cytokines (Abe and Barber, 2014). Paradoxically, STI NG 
also limits autoantibody generation and type I IFN produc-
tion as well as nephritis in lupus-prone mice (Sharma et al., 
2015). Furthermore, STI NG deficiency unexpectedly led to 
hyperresponsiveness of macrophages to TLR7 and TLR9 li-
gands (Sharma et al., 2015). Thus, in addition to its effects on 
type I IFN signaling, the STI NG N153S mutation is likely to 
influence multiple cellular and immunological pathways in a 
variety of ways that also could contribute to disease.
A prior study found that STI NG regulates T cell pro-
liferation in cell culture independently of IRF3 (Cerboni et 
al., 2017). Consistent with these previous in vitro findings 
that used SAVI patient cells with the V155M mutation, we 
demonstrated that the STI NG N153S mutation affects T cells 
in mice in an IRF3-independent manner, and that this was 
caused by hematopoietic cell-intrinsic effects. In addition to 
altered proliferation of T cells, our mixed bone marrow chi-
Figure 7. CyTOF analysis of thymocytes from WT and STI NG N153S mice. Thymocytes were harvested from 4–6-mo-old WT and STI NG N153S mice 
and analyzed by CyTOF. (A) viSNE map of representative WT and STI NG N153S thymocyte populations illustrating color-coded cell populations that were 
clustered together based on similarity in cell surface marker expression. (B) Contour plots of viSNE maps illustrating the density of cell populations as de-
fined in A. (C–M) The total number of thymocytes was determined. The percentage of thymocytes labeled with each of the respective surface markers was 
measured by CyTOF and used to calculate the total numbers of CD45+ cells (C). Percentages of other populations are displayed as follows: CD4−CD8− (double 
negative; D), CD4+CD8+ (double positive; E), CD4+ (F), CD8+ (G), CD19+ (H), NK1.1+(I), CD25−CD44+ (DN1; J), CD25+CD44+ (DN2; K), CD25+CD44− (DN3; L), and 
CD25−CD44− (DN4; M) cells. (N) Percentage Thy1.1− WT littermate or STI NG N153S double-negative thymocytes from mixed bone marrow chimeras. Data in 
C–M represent the mean of samples from n = 6 mice per genotype from two independent experiments analyzed by Mann-Whitney test. **, P < 0.005. Data 












mera studies revealed that STI NG N153S impacts T cells at 
the early stages of thymocyte development. Similar to the 
effects of STI NG N153S on T cells, myeloid cell expansion 
in the STI NG N153S mice also occurred independently of 
IRF3. Because the STI NG N153S mice develop immune 
cell abnormalities resembling those observed in SAVI pa-
tients, future therapeutic studies will determine whether WT 
bone marrow transplantation into STI NG N153S recipients 
may protect animals from disease, which may have implica-
tions for clinical practice.
In summary, our STI NG N153S knock-in mouse 
model demonstrates a role for a human disease–causing 
mutation in immune cell homeostasis and inflammatory 
lung and skin disease in mice. This mouse model will serve 
as an important tool to define mechanisms of STI NG- 
induced autoinflammatory disease, including type I IFN- 




The goal of our study was to define the disease phenotype of 
mice heterozygous for the STI NG N153S mutation. Power 
analysis was conducted for institutional animal care and use 
committee–approved in vivo studies to determine the number 
of animals needed per experimental group. A minimum of two 
independent in vivo experiments were conducted to replicate 
findings. No randomization of animals was used for experi-
ments, but WT littermate control animals were used in all stud-
ies of STI NG N153S mice. No outliers were excluded from 
Figure 8. STI NG N153S mice exhibit al-
tered immune cell signaling. (A and B) 
Splenocytes were harvested from 4–6-mo-old 
WT and STI NG N153S mice and analyzed by 
CyTOF. (A) Representative SPA DE plots of 
phospho-TBK1 (top) and phospho-S6 (bottom) 
in WT and STI NG N153S splenocytes. Size of 
nodes reflects the cell number, and color re-
flects transformed median intensities of the 
phosphoprotein signal. (B) Heat maps depict-
ing calculated arcsinh ratios of median intensi-
ties of phosphoprotein signal in WT and STI NG 
N153S splenocytes. Data were pooled from 
two independent experiments with n = 6 mice. 
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Figure 9. STI NG N153S triggers perivascular pulmonary inflammation, myeloid cell expansion, and T cell cytopenia independently of IRF3. (A) 
Expression of ISGs in STI NG N153S, STI NG knockout (Sting−/−), and Trex1−/− MEFs as well as STI NG N153S and Sting−/− spleens. Each data point represents 
a unique ISG as fold increase compared with a WT littermate control. Data were assembled using ISG expression values from RNA-sequencing. (B) qRT-PCR 
analysis of ISGs in WT, STI NG N153S, Sting−/− MEFs. mRNA expression is normalized to WT. (C) ISG expression in two healthy control (HC) and SAVI patient 
skin fibroblasts. Data represent a selection of ISGs assembled from RNA-sequencing. (D) qRT-PCR analysis of ISGs in skin fibroblasts. Data are from two 
independent experiments with two technical replicates per ISG, normalized to HC. (E) Hematoxylin and eosin images of lungs from Irf3−/− and Irf3−/− STI NG 
N153S mice (4–6 mo of age). Pulmonary vessels are indicated (v) with black arrows highlighting perivascular immune cell infiltration. Pulmonary vessels 
are indicated (v) with arrows. Bar, 100 µm. (F) Quantitation of perivascular lung lesions in STI NG N153S (n = 7) and Irf3−/− N153S (n = 4) mice. Results in 
F represent the mean ± SEM of data collected and analyzed in two independent experiments. (G) ISG mRNA expression in Irf3−/− and Irf3−/− N153S MEFs 
normalized to gene expression in Irf3−/− MEFs. Data represent the mean ± SEM from two independent experiments with n = 3 biological replicates per 












analyses. There was no blinding with regard to data analyses 
with the exception of histological analysis, which was carried 
out in a blinded fashion. The number of technical and biologi-
cal replicates for each experiment is listed in the figure legends.
Study approvals
Patient fibroblasts were provided by R. Goldbach-Mansky 
(NIA ID, NIH, Bethesda, MD), were de-identified, and were 
studied under UT Southwestern Medical Center institutional 
review board approval for de-identified human samples. Ani-
mal protocols were approved by the Institutional Animal Care 
and Use Committees at the Washington University School of 
Medicine (assurance no. A-3381-01) and UT Southwestern 
Medical Center (assurance no. APN2011-0081).
Generation of STI NG N153S knock-in mice
A single guide RNA (sgRNA; 5′-GTT AAA TGT TGC CCA 
CGG GCT GG-3′) was designed based on specificity and prox-
imity to the targeted Tmem173 (STI NG) mutation site. Effi-
ciency of genomic DNA cutting was tested in an in vitro cell 
line assay as previously described (Parikh et al., 2015). T7 tem-
plates for gRNA and WT Cas9 (px330) were prepared by PCR 
amplification and purified by Qiaquick PCR purification spin 
columns (Qiagen). RNA synthesis was then performed accord-
ing to the manufacturer’s protocol using the Megashortscript 
kit (Thermo Fisher Scientific) and mMES SAGE mMAC 
HINE T7 Ultra kit (Thermo Fisher Scientific), for sgRNA and 
Cas9 mRNA, respectively. RNA was purified using MEGA-
clear RNA purification kit (Life Technologies; sgRNA) or by 
lithium chloride precipitation (Cas9 mRNA) and diluted in 
nuclease-free injection buffer. A single-stranded oligonucle-
otide donor (ssODN) encoding the amino acid substitution 
(N153S) with 99-nucleotide homology arms was synthesized 
by IDT (Ultramer oligo): 5′-gctttggacatcccccttgaaagtccctcag-
gcccttctgctgtcttcagAGC TTG ACT CCA GC-GGA AGT CTC 
TGC AGT CTG TGA AGA AAA GAA GTTAtcTGT TGC 
CCA CGG GCT GGC CTG GTC ATA CTA CAT TGG GTA 
CTT GCG GTT GAT CTT ACC AGgtagggcacctctggatgttgat-
gtgtggacaacaaaacac-3′ (exonic sequence in uppercase, flank-
ing intronic sequence in lowercase, and mutant nucleotides in 
underlined lowercase). Female C57BL/6N mice, 4 wk of age, 
were superovulated and mated with C57BL/6N males. Sin-
gle-cell embryos (embryonic day 0.5 [E0.5]) were isolated and 
injected with a combination of either 50 ng/μl Cas9, 25 ng/
μl gRNA, and 100 ng/μl ssODN or a combination of 25 ng/
μl Cas9, 13 ng/μl gRNA, and 100 ng/μl ssODN in DNase/
RNase-free microinjection buffer (1 mM Tris and 0.25 mM 
EDTA, pH 7.4). Over the course of 6 d of microinjection, 
∼80–100 modified embryos per day were transferred into E0.5 
pseudo-pregnant ICR/CD1 female recipient mice. Two in-
dependent founder mice were backcrossed to WT animals for 
five generations, and WT littermate controls were used for all 
experiments. Experiments were performed on mice between 
12 and 24 wk of age, including equal numbers of mice of both 
sexes, with matched littermate control animals. Sample sizes 
were chosen according to our previously published studies. 
Mice were randomly allocated for all experiments.
Mice
Mice were housed in pathogen-free mouse facilities at the 
Washington University School of Medicine and UT South-
western Medical Center and given standard diet and water ad 
libitum. ICR/CD1 mice were provided by the Hope Trans-
genic Mouse Core at Washington University in St. Louis. 
Sting−/− mice were gifts from G. Barber (University of Miami, 
Miami, FL). The congenic backcrossed Irf3−/− mice (Sato et 
al., 2000) were gifts of T. Taniguchi (Tokyo, Japan) and pro-
vided by colleagues in the United States (I. Rifkin, Boston, 
MA; K. Fitzgerald, Worcester, MA).
Generation of mixed bone marrow chimeras
Femurs, tibias, and pelvises were dissected from STI NG 
N153S, WT littermate controls, and Thy1.1 mice. Bone mar-
row was flushed from bones, and red blood cells were lysed 
with ACK lysis buffer. Debris was removed by passing cells 
through a 70-µM strainer and counted via hemocytometer. 
WT or STI NG N153S bone marrow was mixed with Thy1.1 
bone marrow at a 1:1 ratio, and a total of 10 × 106 cells were 
transplanted into CD45.1 hosts via retroorbital i.v. injection. 
Hosts received two doses of whole-body irradiation (500 rads, 
total 1,000 rads) 5 h apart, 24 h before transplantation. Chime-
ras were bled 6 wk after transplantation for FACS analysis of 
circulating immune cells. Three animals per group were euth-
anized ∼10 wk after transplantation for analysis of thymocytes.
Antibodies and other reagents
Antibodies used for flow cytometry include the following: 
FITC–anti-CD19 (rat IgG2a; 1:200, #115506; BioLegend), 
PE–anti-CD45.1 (mouse [A.SW] IgG2a; 1:100, #110707; 
BioLegend), PE/Cy7–anti-Thy1.1 (mouse IgG1; 1:100, 
#202518; BioLegend), BV421–anti-CD4 (rat IgG2b; 1:150, 
#100438; BioLegend), APC–anti-CD45.2 (mouse [SJL] 
IgG2a; 1:100, #109813; BioLegend), V500–anti-CD3e (Syr-
ian hamster IgG2; 1:50, #560771; BD Biosciences), FITC–
anti-CD25 (rat IgG2b; 1:100, #101907; BioLegend), PerCP/
Cy5.5–anti-CD19 (rat IgG2a; 1:100, #152405, BioLegend), 
PerCP/Cy5.5–anti-NK1.1 (mouse IgG2a; 1:100, #108727; 
BioLegend), PerCP/Cy5.5–anti-CD8b (rat IgG2b; 1:100, 
#126609; BioLegend), BV605–anti-CD44 (rat IgG2b; 1:100, 
#103047; BioLegend), FITC–anti-CD8a (rat IgG2a; 1:100, 
STI NG N153S mice. Data represent the mean of two independent experiments with n = 4 or 5 mice per genotype. (K and L) Percentage (K) and total number 
(L) of CD8+ splenocytes from WT, STI NG N153S, Irf3−/−, and Irf3−/− STI NG N153S mice. Data were pooled from two independent experiments with n = 4 or 
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#100705; BioLegend), BV510–anti-CD11b (rat IgG2b; 1:100, 
#101245; BioLegend), BV421–anti-Ly6C (RçAT IgM; 1:100, 
#562727; BD Biosciences), and PerCP/Cy5.5–anti-Ly6G 
(rat IgG2a; 1:100, #127615; BioLegend). For mass cytome-
try experiments, metal-tagged antibodies were obtained from 
Fluidigm or conjugated using the Maxpar X8 Antibody La-
beling kit according to the manufacturer’s instructions (Flu-
idigm). Clone and tag information can be found in Table S1.
Genotyping
Toe clips were digested with proteinase K, and DNA was 
isolated with the Qiagen kit per manufacturer’s protocol. Two 
separate PCR reactions were performed for genotyping: a 
WT allele PCR and a STI NG N153S mutant allele PCR. 
WT primer (5′-GTC TGT GAA GAA AAG AAG TTA AA-3′) 
or STI NG N153S forward primer (5′-GTC TGT GAA GAA 
AAG AAG TTA AC-3′) and reverse primer (5′-GTG ATT 
TTA TGT ACC CTG GG-3′) recognizing sequences in exon 
5 of Tmem173 (STI NG) were added to PCR SuperMix (In-
vitrogen) at a final concentration of 0.4 µM. PCR was per-
formed with an initial denaturation (94°C, 2 min), followed 
by 34 cycles of denaturation (94°C, 30  s), annealing (47°C, 
45  s), and extension (72°C, 1 min). Mice positive for the 
STI NG N153S mutation were identified by the appearance 
of a 258-bp band by agarose gel electrophoresis.
Primary cell isolation and culture
Primary WT littermate, heterozygous STI NG N153S, Irf3−/−, 
Irf3−/− heterozygous STI NG N153S, and Sting−/− MEFs 
(Ishikawa and Barber, 2008; gift from G. Barber) were gen-
erated from embryos on E13.5. MEFs were transfected with 
SV2 plasmid, encoding the large T antigen of SV40 poly-
omavirus. Cells were passaged ∼10 times and used for sub-
sequent experiments. In some experiments, primary MEFs 
were used to confirm phenotypes observed in transformed 
MEFs. Cell lines were genotyped to confirm their identity. 
Human fibroblasts were generated from SAVI patients and 
healthy controls (Liu et al., 2014; gift to the Yan laboratory 
from R. Goldbach-Mansky). All cells were cultured at 37°C 
with 5% CO2 in DMEM supplemented with 10% FBS and 
2  mM l-glutamine, 1× nonessential amino acid solution, 
1 mM sodium pyruvate, 10 mM Hepes, 100 U/ml penicillin, 
and 100 mg/ml streptomycin.
Cytokine assay
Mouse serum was collected by terminal exsanguination of 
anesthetized mice and stored at −20°C before measure-
ment of cytokine and chemokine levels on the Luminex 
platform using the Bio-Plex Pro Mouse Cytokine Group I 
Panel 23-Plex Assay kit (Bio-Rad). The BioPlex Pro Assay 
was performed according to the manufacturer's protocol. Cy-
tokines and chemokines tested include IL-1α, IL-1β, IL-2, 
IL-3 IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-
13, IL-17, eotaxin, G-CSF, GM-CSF, IFN-γ, Iα, MIP-1β, 
RAN TES (CCL5), and TNF.
Autoantigen arrays
Autoantigen arrays were performed on serum samples by the 
University of Texas Southwestern Medical Center Microarray 
Core as previously described (Li et al., 2005).
Stimulation of cell lines with cGAS-STI NG ligands
Transfections of 2′3′-cGAMP (Invivogen), htDNA (Sigma- 
Aldrich), and poly I:C (Sigma-Aldrich) were performed 
using Lipofectamine 2000 (Thermo Fisher Scientific) as pre-
viously described (Dobbs et al., 2015). After 6 h of treatment, 
RNA was isolated using Trizol (Sigma-Aldrich), and ISGs 
and IFN-β were measured via qRT-PCR.
qRT-PCR
Total RNA was isolated by RNeasy kit (Qiagen) per man-
ufacturer’s protocol. RNA was quantified and quality con-
firmed using a NanoDrop ND-1000 spectrophotometer. 
cDNA was synthesized with iScript cDNA synthesis kit (Bio-
Rad). iTaq Universal SYBR Green Supermix (Bio-Rad) and 
an ABI-7500 Fast Real-Time PCR system (Applied Biosys-
tems) were used for qRT-PCR. Alternatively, in some exper-
iments, TaqMan RNA-to-Ct 1-Step kit (Applied Biosystems) 
was used to measure mRNA expression. Ct values for all tar-
get genes were normalized to Ct values of the housekeeping 
gene GAP DH. Data are reported as ΔCt (Cttarget – CtGAP DH).
CyTOF
Spleen and thymus tissues were isolated from WT and STI NG 
N153S mice and mashed through 70-µm Nylon cell strainers, 
washed twice with culture media, and treated with RBC lysis 
buffer. Cells were then washed with CyFACS (0.1% BSA, 
2 mM EDTA, and 0.02% NaN2 in PBS; Rockland) followed 
by CyPBS. For viability staining, cells were incubated with 
2.5 µM cisplatin for 1 min at room temperature, washed twice 
in CyFACS, and fixed in 1.5% PFA (final concentration) for 10 
min at room temperature. After two washes, 3 × 106 cells per 
sample were incubated for 10 min with Fc block, after which 
a cocktail of 17 surface markers (Table S1) was added and in-
cubated with the cells for 1 h on ice. Cells were washed in Cy-
FACS and permeabilized with ice-cold methanol overnight at 
−20°C. The next day, cells were washed twice with CyFACS 
and incubated with a cocktail of 11 intracellular antibodies on 
ice for 1 h (Table S1). Cells were washed, suspended in CyPBS 
containing iridium-intercalator (DNA stain; Fluidigm) and 
2% PFA, and stored at 4°C overnight. Before acquisition on 
a CyTOF2 mass cytometer (Fluidigm), cells were counted, 
washed with ddH2O water, and suspended in EQ Four El-
ement calibration beads (Fluidigm) per the manufacturer’s 
instructions. Normalization was performed using Normalizer 
v0.3 Matlab Complier Runtime (GitHub; Nolan laboratory), 
and Cytobank (cytobank.org) was used for data analysis and 
generation of SPA DE trees, viSNE maps, and heat maps. 
Splenocyte populations were clustered in each viSNE map by 
CD45, CD4, CD8α, CD11b, Ly6G, CD3ε, CD19, NK1.1, and 












CD45, TCRβ, CD4, CD8α, CD11b, Ly6G, TER119, TCRγδ, 
B220, CD3ε, CD19, NK1.1, CD117, and MHC II. Natural 
separations in the viSNE map combined with marker-depen-
dent color-coding of dot plots were used to manually draw 
gates and define populations. Cell populations represented in 
SPA DE trees and heat maps were also manually defined ac-
cording to cell surface marker expression as explained in Table 
S2. For analysis of heat map data and comparison of signal 
intensity, log10 scales were compressed according to the arcsinh 
transformation as previously described (Bendall et al., 2011) 
and in accordance with the standard analytical procedure for 
mass cytometry data on cytobank.org.
Staining of tissue
Tissue was isolated from STI NG N153S, WT littermate con-
trol, Irf3−/−, and Irf3−/− STI NG N153S mice, fixed in 4% 
PFA for 24 h at 4°C, and resuspended in 70% ethanol be-
fore being embedded in paraffin blocks. Tissue sections were 
subjected to hematoxylin and eosin or Gomori trichrome 
staining. Samples were imaged using a Nikon Eclipse E400 
microscope and NIS Elements software. The percentage of 
lung comprised of perivascular inflammatory lesions in each 
mouse was determined by averaging the measurements of 
two random fields using ImageJ (Schneider et al., 2012).
Flow cytometry
Immunophenotyping of spleens was performed on a 
FAC SCanto flow cytometer (BD Biosciences) and analyzed 
using FlowJo software.
Statistics
Unless otherwise specified, all data were analyzed using Graph-
Pad Prism software by Mann–Whitney or t test as specified in 
the figure legends. Flow cytometry data were analyzed using 
FlowJo, and CyTOF results were analyzed using cytobank.org.
Online supplemental material
Supplemental material associated with this study includes 
FACS characterization of infiltrating immune cells in the 
lungs of STI NG N153S mice (Fig. S1), as well as a com-
parison of type I IFN and ISG induction in patient and 
mouse fibroblasts and also in transfected 293T cells (Fig. 
S2). Supplemental tables include CyTOF panels (Table 
S1) and definitions of immune cell populations from 
CyTOF analysis (Table S2).
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Figure S1. Pulmonary immune cell analysis of WT and STI NG N153S mice. (A–F) Flow cytometry analysis of immune cells isolated from the lungs of 
WT and STI NG N153S mice. Total numbers were determined for the following immune cell subsets: CD3+ (A), CD4+ (B), CD8+ (C), CD19+ (D), CD11b+ (E), and 
CD49b+ populations (F). Data represent the mean ± SEM of n = 3 mice per group. *, P < 0.05, ***, P < 0.0005 by unpaired t test.
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Figure S2. IFN-β and ISG expression in primary STI NG N154S patient skin fibroblasts, STI NG N153S MEFs, and transfected 293T cells. (A–F) 
Cells were stimulated with increasing amounts of 2′3′-cGAMP (2, 4, and 8 µg), herring testes DNA (htDNA; 0.1, 0.5, and 1 µg) and polyinosinic–polycytidylic 
acid (poly I:C; 0.1, 0.5, and 1 µg) for 6 h. There was no significant difference cGAMP-transfected WT and STI NG N153S MEFs or between healthy control and 
STI NG N154S skin fibroblasts. Data were analyzed by ANO VA. (G) ISG expression in 293T cells 24 h after overexpression of WT mouse or mutant STI NG N153S 
as previously described (Dobbs et al., 2015). ***, P < 0005; ****, P < 0.0001 by t test. Stimulations were performed in biological triplicates, and qRT-PCR was 
performed in technical triplicates. Data represent the mean ± SEM.
S17JEM 
Table S1. Antibodies used in CyTOF
Tag Target Clone Manufacturer Catalog #
089Y CD45 30-F11 Fluidigm 3089005B
141Pr pSHP2 D66F10 Fluidigm 3141002A
142Nd Caspase 3 (Cleaved) D3E9 Fluidigm 3142004A
143Nd TCRβ H57-597 Fluidigm 3143010B
145Nd CD4 RM4-5 Fluidigm 3145002B
146Nd CD8α 53-6.7 Fluidigm 3146003B
147Sm pSTAT5 47 Fluidigm 3147012A
148Nd CD11B (Mac-1) M1/70 Fluidigm 3148003B
149Sm p4E-BP1 236B4 Fluidigm 3149005A
150Nd CD25 3C7 Fluidigm 3150002B
151Eu Ly-6G 1A8 Fluidigm 3151010B
153Eu pSTAT1 58D6 Fluidigm 3153003A
154Sm TER119 TER-119 Fluidigm 3154005B
155Gd pTBK1/NAK D52C2 CST 5483BF
158Gd pSTAT3 4/P-Stat3 Fluidigm 3158005A
159Tb TCRγδ GL3 Fluidigm 3159012B
160Gd CD45R (B220) RA3-6B2 Fluidigm 3160012B
161Dy pBAD 40A9 Fluidigm 3161006A
164Dy IκBα L35A5 Fluidigm 3164004A
165Ho CD3ε 145-2C11 Fluidigm 3165020B
166Er CD19 6D5 Fluidigm 3166015B
168Er Ki67 B56 Fluidigm 3168007B
170Er NK1.1 PK136 Fluidigm 3170002B
171Yb CD44 IM7 Fluidigm 3171003B
172Yb pS6 N7-548 Fluidigm 3172008A
173Yb CD117 (c-kit) 2B8 Fluidigm 3173004B
174Yb MHC II M5/114.15.2 Fluidigm 3174003B
176Yb pCREB 87G3 Fluidigm 3176005A
Table S2. Definition of populations used in CyTOF analysis
Cell populations Marker expression
Fig. 5
CD4 (CD4 T cells) CD45+ TER119− CD3+ CD4+ TCRβ+
CD8 (CD8 T cells) CD45+ TER119− CD3+ CD8+ TCRβ+
NK (NK cells) CD45+ TER119− NK1.1+ CD3−
CD19 (B cells) CD45+ TER119− CD19+ B220+ MHC II+/int/lo
Ly6G+ (CD11bhi Ly6Ghi) CD45+/lo TER119− CD11bhi Ly6Ghi
Monocytes CD45+ TER119− CD11b+ Ly6G− MHC II−
Immature myeloid CD45lo TER119− CD117+/lo CD11b+ Ly6Gint/lo/-
CD3 double-negative (DN) CD45+ TER119− CD3+ CD4− CD8−
Fig. 6
CD4+ CD8− CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8−
CD8+ CD4− CD45+ TER119− B220− CD19− NK1.1− CD8+ CD4−
CD4+ CD8+ CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8+
CD4− CD8− CD45+ TER119− B220− CD19− NK1.1− CD4− CD8−
CD19+ B220+ CD45+ TER119− B220+ CD19+
NK1.1+ CD45+ TER119− B220− CD19− NK1.1+
DN1 CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8+ CD44+ CD25−
DN2 CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8+ CD44+ CD25+
DN3 CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8+ CD25+ CD44 lo/-
DN4 CD45+ TER119− B220− CD19− NK1.1− CD4+ CD8+ CD44lo/− CD25−
Fig. 7
B cells CD45+ TER119− CD3− CD19+
T cells CD45+ TER119− CD19− CD3+
Monocytes CD45+ TER119− CD3− CD19− CD11b+ Ly6G− MHC II−
NK cells CD45+ TER119− CD19− CD3− NK1.1+
Immature myeloid CD45+ TER119− CD3− CD19− CD11b+ MHC II−
Mouse model of STI NG-associated vasculopathy | Warner et al.S18
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